BookAntoinette Maassen van den Brink, Paolo Martelletti, editors.
Summary: Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Contents:
The CGRP family of neuropeptides and their receptors in the trigeminovascular system
Pharmacology; where do the mAbs act, gepants vs mAbs
Monoclonal Antibody Biology
Guidelines for clinical trials
Human Models
CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders
Galcanezumab
Eptinezumab
Erenumab
Fremanezumab
Potential side effects and pregnancy
Real-world data, clinical practice so far
Migraine vs Cluster headache and potential other indications.